Article: Diagnosis and management of pulmonary hypertension related to chronic respiratory disease.
2023 Volume 18, Issue 4, Page(s) 220205
Abstract: Pulmonary hypertension (PH) is a recognised and significant complication of chronic lung disease (CLD) and hypoxia (referred to as group 3 PH) that is associated with increased morbidity, decreased quality of life and worse survival. The prevalence and ... ...
Abstract | Pulmonary hypertension (PH) is a recognised and significant complication of chronic lung disease (CLD) and hypoxia (referred to as group 3 PH) that is associated with increased morbidity, decreased quality of life and worse survival. The prevalence and severity of group 3 PH varies within the current literature, with the majority of CLD-PH patients tending to have non-severe disease. The aetiology of this condition is multifactorial and complex, while the prevailing pathogenetic mechanisms include hypoxic vasoconstriction, parenchymal lung (and vascular bed) destruction, vascular remodelling and inflammation. Comorbidities such as left heart dysfunction and thromboembolic disease can further confound the clinical picture. Noninvasive assessment is initially undertaken in suspected cases ( |
---|---|
Language | English |
Publishing date | 2023-01-10 |
Publishing country | England |
Document type | Journal Article ; Review |
ZDB-ID | 2562899-9 |
ISSN | 2073-4735 ; 1810-6838 |
ISSN (online) | 2073-4735 |
ISSN | 1810-6838 |
DOI | 10.1183/20734735.0205-2022 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.